U.S. Jury Says CareDx Owes Natera $96 Million in a Genetic-Testing Patent Case

A jury in Delaware federal court has awarded genetic-testing company Natera NTRA.O more than $96.3 million in damages after finding that rival CareDx’s CDNA.O AlloSure and AlloSeq kidney-transplant tests infringe a Natera patent, according to a verdict made public on Monday.

The jury determined that Natera was entitled to more than $83.6 million in lost profits and $12.6 million in royalties from CareDx. The Friday verdict came after the same jury concluded earlier in the day that CareDx had infringed one of Natera’s two patents at issue in the case.

CareDx said in a court filing that Natera had sought more than $149 million in lost-profit damages.

Read the source article at Nasdaq